The DOI matches its Crossref record; 60 of the 64 references it cites were found in a registry or an index.
Crosstalk between Insulin/Insulin-like Growth Factor-1 Receptors and G Protein-Coupled Receptor Signaling Systems: A Novel Target for the Antidiabetic Drug Metformin in Pancreatic Cancer
Open accessAbstract
Insulin/insulin-like growth factor 1(IGF-1) receptors and G protein-coupled receptors (GPCR) signaling systems are implicated in autocrine-paracrine stimulation of a variety of malignancies, including ductal adenocarcinoma of the pancreas, one of the most lethal human diseases. Novel targets for pancreatic cancer therapy are urgently needed. We identified a crosstalk between insulin/IGF-1 receptors and GPCR signaling systems in pancreatic cancer cells, leading to enhanced signaling, DNA synthesis, and proliferation. Crosstalk between these signaling systems depends on mammalian target of rapamycin (mTOR) complex 1 (mTORC1). Metformin, the most widely used drug in the treatment of type 2 diabetes, activates AMP kinase (AMPK), which negatively regulates mTORC1. Recent results show that metformin-induced activation of AMPK disrupts crosstalk between insulin/IGF-1 receptor and GPCR signaling in pancreatic cancer cells and inhibits the growth of these cells in xenograft models. Given that insulin/IGF-1 and GPCRs are implicated in other malignancies, a similar crosstalk mechanism may be operative in other cancer cell types. Recent epidemiological studies linked administration of metformin with a reduced risk of pancreatic, breast, and prostate cancer in diabetic patients. We posit that crosstalk between insulin/IGF-1 receptor and GPCR signaling is a mechanism for promoting the development of certain types of cancer and a target for the prevention and therapy of these diseases via metformin administration. Clin Cancer Res; 16(9); 2505–11. ©2010 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Prior studies with KRAS G12C , RAF, and MEK inhibitors indicated that blockade of KRAS-dependent signaling activated a transcriptional program suppressing DUSP , SPRY , and ETV family genes which cooperate to mediate increased signaling flux though RTK, SOS, and MEK/ERK family members resulting in conditional bypass dependence on KRAS [4, 32-34].”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849
Kahn, B. B., Alquier, T., Carling, D., & Hardie, D. G. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2004.12.003 · Cited by 2,799
Critical nodes in signalling pathways: insights into insulin action
Taniguchi, C. M., Emanuelli, B., & Kahn, C. R. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1837 · Cited by 2,760
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950
PI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845
Growing roles for the mTOR pathway
Sarbassov, D. D., Ali, S. M., & Sabatini, D. M. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.09.009 · Cited by 1,590
G-protein-coupled receptors and cancer
Dorsam, R. T., & Gutkind, J. S. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2069 · Cited by 1,448 · cited 8×
“Insulin/IGF-1 and GPCR signaling pathways crosstalk through mTORC1.”
BackgroundInfluentialEarly Signals in the Mitogenic Response
Rozengurt, E. (1986) · Science · doi:10.1126/science.3018928 · Cited by 1,444 · cited 1×
“At the cellular level, insulin dramatically synergizes with GPCR agonists in inducing mitogenic signaling (3), and many GPCRs and their cognate agonists are implicated as autocrine-paracrine growth factors for multiple solid tumors, including pancreas, colon, prostate, and breast (1, 4).”
BackgroundSelf-citationInoki, K., Ouyang, H., Zhu, T., Lindvall, C., Wang, Y., Zhang, X., Yang, Q., Bennett, C., Harada, Y., Stankunas, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.06.055 · Cited by 1,377
Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N., & Struhl, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2994 · Cited by 1,115
The LKB1 tumor suppressor negatively regulates mTOR signaling
Shaw, R. J., Bardeesy, N. M., Manning, B. D., Lopez, L. V., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,107
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1500 · Cited by 1,048
Insulin Activation of Rheb, a Mediator of mTOR/S6K/4E-BP Signaling, Is Inhibited by TSC1 and 2
Garami, A., Zwartkruis, F. J. T., Nobukuni, T., Joaquin, M., Roccio, M., Stocker, H., Kozma, S. C., Hafen, E., Bos, J. L., & Thomas, G. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00220-x · Cited by 1,043
New Users of Metformin Are at Low Risk of Incident Cancer
Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D., & Evans, J. M. M. (2009) · Diabetes Care · doi:10.2337/dc08-2175 · Cited by 996
Buzzai, M., Jones, R. G., Amaravadi, R. K., Lum, J. J., DeBerardinis, R. J., Zhao, F., Viollet, B., & Thompson, C. B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4447 · Cited by 949
Dowling, R. J. O., Zakikhani, M., Fantus, I. G., Pollak, M., & Sonenberg, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2310 · Cited by 933
Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins
Zhang, Y., Gao, X., Saucedo, L. J., Ru, B., Edgar, B. A., & Pan, D. (2003) · Nature Cell Biology · doi:10.1038/ncb999 · Cited by 924
Specificity in Signal Transduction
Pawson, T. J. (2004) · Cell · doi:10.1016/s0092-8674(03)01077-8 · Cited by 821
Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1
Um, S. H., D'Alessio, D., & Thomas, G. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.05.003 · Cited by 690 · cited 13×
“We hypothesize that the concomitant activation of the PI3K/ Akt pathway (via insulin/IGF-1 receptor), the Gq/PLC/ PKD/ERK pathway (via agonist-induced Gq signaling and enhanced by insulin/IGF-1 signaling), and mTORC1 (synergistically by insulin/IGF-1-induced PI3K/Akt and GPCRstimulated ERK/p90RSK) in pancreatic cancer…”
BackgroundInfluentialInsulin signaling pathways in time and space
Saltiel, A. R., & Pessin, J. E. (2002) · Trends in Cell Biology · doi:10.1016/s0962-8924(01)02207-3 · Cited by 627 · cited 2×
“Although the signaling pathways activated by either GPCR agonists or insulin/IGF-1 have been the subject of intense scrutiny (1, 23, 24, 41),much less is known about the mechanisms by which these pathways crosstalk in pancreatic cancer cells or in any other cell type.”
BackgroundBinding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice
Gupta, S., Ramjaun, A. R., Haiko, P., Wang, Y., Warne, P. H., Nicke, B., Nye, E. L., Stamp, G., Alitalo, K. K., & Downward, J. (2007) · Cell · doi:10.1016/j.cell.2007.03.051 · Cited by 603
Antidiabetic Therapies Affect Risk of Pancreatic Cancer
Li, D., Yeung, S. J., Hassan, M. M., Konopleva, M., & Abbruzzese, J. L. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.013 · Cited by 584
Hunyady, L., & Catt, K. J. (2006) · Molecular Endocrinology · doi:10.1210/me.2004-0536 · Cited by 541
Giovannucci, E. L., & Michaud, D. S. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.050 · Cited by 538
Mitogenic signaling pathways induced by G protein‐coupled receptors
Rozengurt, E. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21246 · Cited by 465
Self-citationRozengurt, E., Rey, O., & Waldron, R. T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.r500002200 · Cited by 437 · cited 1×
“PKCs induce rapid phosphorylation of cytosolic and membrane-bound proteins, including the downstream protein kinases of the PKD family (16).”
BackgroundSelf-citationAMP-Activated Protein Kinase as a Drug Target
Hardie, D. G. (2006) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105304 · Cited by 411
Prevention of pancreatic cancer induction in hamsters by metformin
Schneider, M. B., Matsuzaki, H., Haorah, J., Ulrich, A. B., Standop, J., Ding, X., Adrian, T. E., & Pour, P. M. (2001) · Gastroenterology · doi:10.1053/gast.2001.23258 · Cited by 330
Kisfalvi, K., Eibl, G., Sinnett‐Smith, J. W., & Rozengurt, E. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0418 · Cited by 321 · cited 5×
“Recently, we identified a novel crosstalk between insulin/IGF-1 receptors and GPCR signaling systems in pancreatic cancer cells (2, 8).”
BackgroundInfluentialSelf-citation4E-Binding Protein 1: A Key Molecular “Funnel Factor” in Human Cancer with Clinical Implications
Armengol, G., Rojo, F., Castellví, J., Iglesias, C., Cuatrecasas, M., Pons, B., Baselga, J. M., & y Cajal, S. R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0881 · Cited by 279
LKB1; linking cell structure and tumor suppression
Hezel, A. F., & Bardeesy, N. M. (2008) · Oncogene · doi:10.1038/onc.2008.342 · Cited by 237 · cited 1×
“The ubiquitously expressed and evolutionarily conserved serine-threonine kinase liver kinase B1/serine-threonine kinase 11 (LKB-1/STK11) represents the major (but not the only) kinase phosphorylating the AMPK activation loop under conditions of energy stress (46).”
BackgroundComplexity of the TOR signaling network
Inoki, K., & Guan, K. (2006) · Trends in Cell Biology · doi:10.1016/j.tcb.2006.02.002 · Cited by 191
Nyman, L. R., Wells, K., Head, W., McCaughey, M., Ford, E., Brissova, M., Piston, D., & Powers, A. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36209 · Cited by 191
Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma
Reubi, J. C., Waser, B., Frieß, H., Büchler, M., & Laissue, J. A. (1998) · Gut · doi:10.1136/gut.42.4.546 · Cited by 186
Phospholipase D1 is an effector of Rheb in the mTOR pathway
Sun, Y., Fang, Y., Yoon, M., Zhang, C., Roccio, M., Zwartkruis, F. J. T., Armstrong, M. D., Brown, H. A., & Chen, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712268105 · Cited by 184
Differential effect of adenosine on tumor and normal cell growth: Focus on the A3 adenosine receptor
Ohana, G., Bar‐Yehuda, S., Barer, F., & Fishman, P. (2000) · Journal of Cellular Physiology · doi:10.1002/1097-4652(200101)186:1 · Cited by 123
Self-citationGuha, S., Rey, O., & Rozengurt, E. (2002) · PubMed · Cited by 114
Self-citationSinnett‐Smith, J. W., Жукова, Е., Hsieh, N., Jiang, X., & Rozengurt, E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313225200 · Cited by 113 · cited 1×
“PKD induces MEK/ERK/p90RSK pathway activation and thereby mediates cell proliferation in some cell types (17, 18).”
BackgroundSelf-citationArafat, H. A., Gong, Q., Chipitsyna, G. I., Rizvi, A., Saa, C. T., & Yeo, C. J. (2007) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2007.01.067 · Cited by 111
Should individual PI3 kinase isoforms be targeted in cancer?
Jia, S., Roberts, T. M., & Zhao, J. J. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.007 · Cited by 107
Guha, S., Eibl, G., Kisfalvi, K., Fan, R. S., Burdick, M. D., Reber, H. A., Hines, O. J., Strieter, R. M., & Rozengurt, E. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3197 · Cited by 102
Self-citationEnhanced expression of the insulin receptor substrate-2 docking protein in human pancreatic cancer.
Kornmann, M., Maruyama, H., Bergmann, U., Tangvoranuntakul, P., Beger, H. G., White, M. F., & Korc, M. (1998) · PubMed · Cited by 89
Guha, S., Lunn, J. A., Santiskulvong, C., & Rozengurt, E. (2003) · PubMed · Cited by 88
Self-citationNakamura, K., Sasajima, J., Mizukami, Y., Sugiyama, Y., Yamazaki, M., Fujii, R., Kawamoto, T., Koizumi, K., Sato, K., Fujiya, M., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008824 · Cited by 86
PKCμ prevents CD95-mediated apoptosis and enhances proliferation in pancreatic tumour cells
Trauzold, A., Schmiedel, S., Sipos, B., Wermann, H., Westphal, S., Röder, C., Klapper, W., Arlt, A., Lehnert, L., Ungefroren, H., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1207001 · Cited by 82
The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation.
Asano, T., Yao, Y.-X., Zhu, J.-J., Li, D.-H., Abbruzzese, J., & Reddy, S. A. (2005) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2005.03.166 · Cited by 74
Yuan, J., & Rozengurt, E. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21439 · Cited by 70 · cited 1×
“PKD is activated in pancreatic cancer cells by GPCR agonists, including neurotensin (6, 19), it is overexpressed in pancreatic cancer tissues (20), and its overexpression promotes pancreatic cancer cell proliferation (21).”
BackgroundSelf-citationSinnett‐Smith, J. W., Jacamo, R. O., Kui, R. K., Wang, Y. M., Young, S. H., Rey, O., Waldron, R. T., & Rozengurt, E. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m806554200 · Cited by 70 · cited 1×
“PKD induces MEK/ERK/p90RSK pathway activation and thereby mediates cell proliferation in some cell types (17, 18).”
BackgroundSelf-citationNeurotensin receptor-1 mRNA analysis in normal pancreas and pancreatic disease.
Wang, L., Frieß, H., Zhu, Z., Graber, H. U., Zimmermann, A., Korc, M., Reubi, J. C., & Büchler, M. W. (2000) · PubMed · Cited by 64
Kisfalvi, K., Guha, S., & Rozengurt, E. (2004) · Journal of Cellular Physiology · doi:10.1002/jcp.20187 · Cited by 57 · cited 1×
“Neurotensin acts as a potent growth factor for pancreatic cancer cells (5, 7, 8, 13), and a broad-spectrum GPCR antagonist inhibited the growth of pancreatic cancer cells either in vitro or xenografted into nu/nu mice (14).”
BackgroundSelf-citationRelevant genomics of neurotensin receptor in cancer.
Elek, J., Pinzon, W., Park, K. H., & Narayanan, R. (2000) · PubMed · Cited by 56
Kisfalvi, K., Rey, O., Young, S. H., Sinnett‐Smith, J. W., & Rozengurt, E. (2007) · Endocrinology · doi:10.1210/en.2006-1711 · Cited by 53
Self-citationAsano, T., Yao, Y., Shin, S., McCubrey, J. A., Abbruzzese, J. L., & Reddy, S. A. G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0779 · Cited by 49 · cited 1×
“This pathway plays a pivotal role in the proliferation and survival of pancreatic cancer cells (30) and is activated in pancreatic cancer tissues (31).”
BackgroundChong, C. R., & Chabner, B. A. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0286 · Cited by 47 · cited 1×
“Other studies observed a lower cancer-relatedmortality rate in patientswith type 2 diabetes who received metformin as compared with other treatments, including exogenous insulin or sulfonylureas (58).”
ResultKisfalvi, K., Hurd, C., Guha, S., & Rozengurt, E. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22036 · Cited by 43
Self-citationSantiskulvong, C., & Rozengurt, E. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.01.006 · Cited by 42
Self-citationKolb, S., Fritsch, R., Saur, D., Reichert, M., Schmid, R. M., & Schneider, G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3308 · Cited by 41 · cited 1×
“Accordingly, pancreatic cancer cells express insulin and IGF-1 receptors and overexpress IRS-1 and IRS-2 (28, 29), underscoring the importance of these pathways in promoting pancreatic cancer proliferation.”
BackgroundBierkamp, C., Bonhoure, S., Mathieu, A., Clerc, P., Fourmy, D., Pradayrol, L., Seva, C., & Dufresne, M. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63263-4 · Cited by 18
Cited by
Sorted by citations
Targeting PI3K/Akt signal transduction for cancer therapy
He, Y., Sun, M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 2,045
FGF/FGFR signaling in health and disease
Xie, Y., Su, N., Yang, J., Tan, Q., Huang, S., Jin, M., Ni, Z., Zhang, B., Zhang, D., Luo, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00222-7 · Cited by 904
G protein-coupled receptors: novel targets for drug discovery in cancer
Lappano, R., & Maggiolini, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3320 · Cited by 742
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
Hallin, J., Bowcut, V., Calinisan, A., Briere, D. M., Hargis, L., Engstrom, L. D., Laguer, J., Medwid, J., Vanderpool, D., Lifset, E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02007-7 · Cited by 553
Metformin: Taking away the candy for cancer?
Jalving, M., Gietema, J. A., Lefrandt, J. D., de Jong, S., Reyners, A. K. L., Gans, R. O. B., & de Vries, E. G. E. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.06.012 · Cited by 382
Metadata
- Authors
- Rozengurt, E., Sinnett-Smith, J., & Kisfalvi, K.
- Affiliations
- University of California, Los Angeles (US)
- Authors' Affiliation: Division of Digestive Diseases, Department of Medicine, CURE: Digestive Diseases Research Center, David Geffen School of Medicine and Molecular Biology Institute, University of California at Los Angeles, Los Angeles California
- Corresponding author
- Rozengurt, Enrique
- ORCID
- Rozengurt, Enrique
- Venue
- Clinical Cancer Research
- Published
- 2010-04-28
- Volume
- 16
- Issue
- 9
- Pages
- 2505-2511
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC2862089
- OpenAlex
- W2158170204
- Cited by
- 247
- References
- 64
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 9 · 2023: 8 · 2022: 12 · 2021: 9 · 2020: 13 · 2019: 12 · 2018: 9 · 2017: 19 · 2016: 20 · 2015: 20 · 2014: 21 · 2013: 30 · 2012: 23
- FWCI
- 10.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R21CA137292)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK56930, P30 DK 41301, R0-1 DK55003, R01DK056930, P30DK041301, R01DK055003)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- metformin, G protein-coupled receptors, pancreatic cancer, mTORC1, AMPK, autocrine and paracrine signaling, cell proliferation, cancer prevention, drug repurposing
- MeSH terms
- Mechanistic Target of Rapamycin Complex 1, Animals, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin, Models, Biological, Pancreatic Neoplasms, Proteins, Receptor, Insulin, Transcription Factors, Signal Transduction, Receptor, IGF Type 1, Receptor Cross-Talk, Receptors, G-Protein-Coupled, Multiprotein Complexes, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
